Literature DB >> 29699267

In vitro growth and maturation of mouse oocyte-granulosa cell complex from cryopreserved ovaries and achievement of pup birth.

Akiko Hasegawa1, Koji Koyama1,2.   

Abstract

Ovarian tissue banking is a feasible strategy for fertility preservation for young women after cancer treatments. Ovarian tissue, after thawing, is used for several options; orthotopic grafting (normal site), autologous heterotopic grafting and collection of ovarian follicles for culture. Recent reports of live birth encouraged clinicians and researchers to apply this technology to premature ovarian failure (POF) resulting from strong cancer therapy. Grafting, however, carries a risk of malignant cell recurrence. For safety, development of a culture method is necessary but optimum culturing conditions for less-developed follicles abundant in the ovary are not well known. In the present article, the current status of ovarian tissue cryopreservation, and in vitro oocyte growth and maturation from the preserved ovaries are reviewed.

Entities:  

Keywords:  cancer; fertilization; infertility; premature ovarian failure; vitrification.

Year:  2007        PMID: 29699267      PMCID: PMC5906896          DOI: 10.1111/j.1447-0578.2007.00169.x

Source DB:  PubMed          Journal:  Reprod Med Biol        ISSN: 1445-5781


  51 in total

1.  In vitro culture of mouse GV oocytes and preantral follicles isolated from ovarian tissues cryopreserved by vitrification.

Authors:  Miwa Segino; Mario Ikeda; Sigeru Aoki; Yuko Tokieda; Fumiki Hirahara; Kahei Sato
Journal:  Hum Cell       Date:  2003-09       Impact factor: 4.174

Review 2.  Cryopreservation of human oocytes and ovarian tissue.

Authors:  Raffaella Fabbri
Journal:  Cell Tissue Bank       Date:  2006       Impact factor: 1.522

3.  Transplantation of cryopreserved human ovarian tissue results in follicle growth initiation in SCID mice.

Authors:  K Oktay; H Newton; R G Gosden
Journal:  Fertil Steril       Date:  2000-03       Impact factor: 7.329

4.  Birth of pups after transfer of mouse embryos derived from vitrified preantral follicles.

Authors:  E C dela Peña; Y Takahashi; S Katagiri; E C Atabay; M Nagano
Journal:  Reproduction       Date:  2002-04       Impact factor: 3.906

5.  Pup birth from mouse oocytes in preantral follicles derived from vitrified and warmed ovaries followed by in vitro growth, in vitro maturation, and in vitro fertilization.

Authors:  Akiko Hasegawa; Nahoko Mochida; Toshitada Ogasawara; Koji Koyama
Journal:  Fertil Steril       Date:  2006-09-11       Impact factor: 7.329

6.  Natural-cycle in vitro fertilization combined with in vitro maturation of immature oocytes is a potential approach in infertility treatment.

Authors:  Ri-Cheng Chian; William M Buckett; Ahmad Kamal Abdul Jalil; Weon-Young Son; Camille Sylvestre; Durga Rao; Seang Lin Tan
Journal:  Fertil Steril       Date:  2004-12       Impact factor: 7.329

Review 7.  Genetic control of early folliculogenesis in mice.

Authors:  Olga Epifano; Jurrien Dean
Journal:  Trends Endocrinol Metab       Date:  2002 May-Jun       Impact factor: 12.015

8.  Livebirth after orthotopic transplantation of cryopreserved ovarian tissue.

Authors:  J Donnez; M M Dolmans; D Demylle; P Jadoul; C Pirard; J Squifflet; B Martinez-Madrid; A van Langendonckt
Journal:  Lancet       Date:  2004 Oct 16-22       Impact factor: 79.321

9.  Live births after vitrification of oocytes in a stimulated in vitro fertilization-embryo transfer program.

Authors:  Tae Ki Yoon; Thomas J Kim; Sung Eun Park; Seung Wook Hong; Jung Jae Ko; Hyung Min Chung; Kwang Yul Cha
Journal:  Fertil Steril       Date:  2003-06       Impact factor: 7.329

10.  Immunohistochemical localization of steroidogenic enzymes in human follicle following xenotransplantation of the human ovarian cortex into NOD-SCID mice.

Authors:  Yumi Sato; Yukihiro Terada; Hiroki Utsunomiya; Yoshio Koyanagi; Mamoru Ito; Ichiro Miyoshi; Takashi Suzuki; Hironobu Sasano; Takashi Murakami; Nobuo Yaegashi; Kunihiro Okamura
Journal:  Mol Reprod Dev       Date:  2003-05       Impact factor: 2.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.